1-[4-Bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea | |
---|---|
Trade Name | |
Orphan Indication | Glioblastoma |
USA Market Approval | USA |
USA Designation Date | 2017-08-07 00:00:00 |
Sponsor | Deciphera Pharmaceuticals, LLC;500 Totten Pond Road;Waltham, Massachusetts, 02451 |